SCHEMBL13250545

SCHEMBL13250545

Brc1ccc(C(c2ccc(CN3CCCNCc4cccc(c4)CNCCC3)cc2)c2ccc(CN3CCCNCc4cccc(c4)CNCCC3)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 12/20 0.48
▸ TDP1 Q9NUW8 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ CHRM2 P08172 1/20 0.45
▸ CHRM1 P11229 1/20 0.45
▸ ADRA2C P18825 1/20 0.45
▸ CCR2 P41597 1/20 0.45
▸ CXCL12 P48061 1/20 0.45
▸ BLM P54132 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ HRH3 Q9Y5N1 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ IGF1R P08069 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ TNIK Q9UKE5 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13250526 0.92 SMN1; SMN2 (0.44) CXCR4TDP1MEN1CHRM2CHRM1
SCHEMBL13250543 0.90 CXCR4 (0.50) CXCR4TDP1MEN1CHRM2CHRM1
SCHEMBL13250546 0.88 CXCR4 (0.48) CXCR4TDP1MEN1CHRM2CHRM1
SCHEMBL13250544 0.88 CXCR4 (0.55) CXCR4TDP1MEN1CHRM2CHRM1
SCHEMBL13250547 0.86 CXCR4 (0.50) CXCR4TDP1MEN1CHRM2CHRM1
SCHEMBL13447599 0.85 CXCR4 (0.52) CXCR4TDP1MEN1CHRM2CHRM1
SCHEMBL13250550 0.85 CXCR4 (0.62) CXCR4TDP1MEN1CHRM2CHRM1
SCHEMBL13250519 0.82 CXCR4 (0.43) CXCR4TDP1MEN1CHRM2CHRM1
SCHEMBL13250509 0.81 CXCR4 (0.70) CXCR4TDP1MEN1CHRM2CHRM1
SCHEMBL13250522 0.81 CXCR4 (0.46) CXCR4TDP1MEN1CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420626-B2 Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2013-04-16 — — US disclosed
US-8420626-B2 Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2013-04-16 — — US disclosed
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2010-07-15 — — US disclosed
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2010-07-15 — — US disclosed
EP-2163553-A1 ARENE CONNECTED POLYAMINE MACRORING DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF Beijing Molecule Science and Technology Co., Ltd. (CN) 2010-03-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof SRM, SP1, SMS CXCR4 555/4885TDP1 1911/4885MEN1 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback